Valens Semiconductor Ltd.·4

Jun 1, 9:32 AM ET

Yarel - Toledano Adi 4

4 · Valens Semiconductor Ltd. · Filed Jun 1, 2026

Research Summary

AI-generated summary of this filing

Updated

Valens (VLN) Director Adi Yarel-Toledano Exercises Options, Sells Shares

What Happened

  • Director Adi Yarel-Toledano exercised a total of 22,325 stock options (5,100 on May 28 and 17,225 on May 29) at $2.39 per share, paying about $53,357 in exercise costs. The resulting shares were sold the same days in open-market transactions for gross proceeds of about $78,709 (sales at ~$3.50 and ~$3.53 per share).
  • This was an exercise followed by immediate sale (a cashless-style outcome), not a buy-and-hold purchase — so it is routine monetization rather than a clear bullish stock purchase.

Key Details

  • Transaction dates and prices:
    • 2026-05-28: Exercised 5,100 options at $2.39 ($12,189); sold 5,100 shares at $3.50 ($17,850).
    • 2026-05-29: Exercised 17,225 options at $2.39 ($41,168); sold 17,225 shares at $3.53 ($60,859).
  • Totals: 22,325 shares exercised (cost ~$53,357) and 22,325 shares sold (proceeds ~$78,709).
  • Shares owned after the transactions: not specified in the provided filing details.
  • Notable footnotes:
    • Sales were made under a Rule 10b5-1 trading plan adopted Dec 1, 2025 (F1).
    • The shares sold were acquired via exercise on the same dates (F2, F3, F5).
    • Reported prices are weighted averages; the filer can provide per-trade details on request (F4).
  • Filing timeliness: Form filed 2026-06-01 for transactions on May 28–29, 2026; no late-filing flag provided in the supplied data.

Context

  • Because the options were exercised and the resulting shares were sold the same day, this is effectively cashing out option value rather than a new purchase of stock — such transactions are common for insiders to realize gains or cover option costs/taxes.
  • The use of a 10b5-1 plan indicates the sales were prearranged, which can reduce concerns about trades being based on nonpublic information but does not imply endorsement of the company’s near-term prospects.
  • For retail investors, purchases by insiders are typically more informative of confidence than same-day option exercises followed by sales; treat this event as routine insider monetization unless further insider accumulation is observed.

Insider Transaction Report

Form 4
Period: 2026-05-28
Transactions
  • Exercise/Conversion

    Ordinary Shares

    [F2]
    2026-05-28$2.39/sh+5,100$12,189169,353 total
  • Sale

    Ordinary Shares

    [F1][F3]
    2026-05-28$3.50/sh5,100$17,850164,253 total
  • Exercise/Conversion

    Ordinary Shares

    [F2]
    2026-05-29$2.39/sh+17,225$41,168181,478 total
  • Sale

    Ordinary Shares

    [F1][F3][F4]
    2026-05-29$3.53/sh17,225$60,859164,253 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F5]
    2026-05-285,10039,550 total
    Exercise: $2.39From: 2024-04-14Exp: 2031-01-15Ordinary Shares (5,100 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F5]
    2026-05-2917,22522,325 total
    Exercise: $2.39From: 2024-04-14Exp: 2031-01-15Ordinary Shares (17,225 underlying)
Footnotes (5)
  • [F1]The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2025
  • [F2]The shares were acquired upon the exercise of stock options
  • [F3]The shares sold were acquired upon the exercise of stock options on the same date
  • [F4]The price reported is a weighted average price. The reporting person undertakes to provide full information, regarding the number of shares and prices at which the transaction was effectuated, upon request.
  • [F5]The options reported herein were exercised and the underlying shares were sold on the same date as reported in Table I.
Signature
/s/ Meirav Shemesh on behalf of Oppenheimer Israel, as Attorney-in-fact|2026-06-01

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT